We're not talking about 10 years. We're talking about 3 years max. But yes, you're right. Taking $50 now instead of $500 in 3 years is hard to justify.
Unless you were talking about taking big risks with your $50
But Neuren is as de-risked as they come.
* Low financial risk (cashed up to the eye balls) * Low product risk (multiple indications, already approved drug, exceptional Ph 2 effectiveness, low to zero side effects) * Low market risk (protected Orphan drug market, all indications have no approved drugs, Neuren likely to be first to market, low competition) * Low sector technology risk (e.g. gene therapy - Barrenjoey analyst report makes a good argument why gene therapy is unlikely to to be a threat at all to Neuren in the medium term future).
I'd personally like some $50 now so I could take some $ off the table... But you'd have to say a low risk play to 40x current share price in 3 years is hard to beat.
NEU Price at posting:
$14.39 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)